| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of ...
Truist Securities analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces ...
Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company d...